Cogstate Limited

Equities

CGS

AU000000CGS8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
1.325 ^AUD	+2.71%		+6.43%	-8.30%

Apr. 01	Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	MT
Feb. 22	Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%	MT

Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2022

August 29, 2022 at 06:29 pm EDT

Cogstate Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was USD 44.98 million compared to USD 32.69 million a year ago. Revenue was USD 45.03 million compared to USD 32.7 million a year ago.

Net income was USD 7.52 million compared to USD 5.23 million a year ago. Basic earnings per share from continuing operations was USD 0.0435 compared to USD 0.0307 a year ago. Diluted earnings per share from continuing operations was USD 0.0425 compared to USD 0.0302 a year ago.

Latest news about Cogstate Limited

Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%	Feb. 21	MT
Cogstate Limited authorizes a Buyback Plan.	Feb. 21	CI
Transcript : Cogstate Limited, H1 2024 Earnings Call, Feb 22, 2024	Feb. 21
Cogstate Limited announces an Equity Buyback for 5,000,000 shares, representing 2.92% of its issued share capital.	Feb. 21	CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 21	CI
Cogstate Ends Share Buyback Program	Dec. 04	MT
Cogstate Limited's Equity Buyback announced on February 28, 2023 has closed with 3,753,218 shares, representing 2.17% for AUD 5.59 million.	Dec. 03	CI
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023.	Dec. 03	CI
Transcript : Cogstate Limited - Special Call	23-10-12
Cogstate Joins Forces to Establish Dementia Insurance in Japan	23-09-28	MT
Cogstate Limited Announces Change of Registered Office and Principal Place of Business	23-09-12	CI
Cogstate Limited Provides Revenue Guidance for 2024	23-08-21	CI
Transcript : Cogstate Limited, 2023 Earnings Call, Aug 22, 2023	23-08-21
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023.	23-08-21	CI
Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-21	CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023	23-05-09	CI
Cogstate Limited Appoints Kristi Geddes as Company Secretary	23-04-27	CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023	23-04-16	CI
Cogstate Limited Reports Revenue Results for the Quarter and Year to Date Ended 31 March 2023	23-04-16	CI
Transcript : Cogstate Limited, H1 2023 Earnings Call, Feb 28, 2023	23-02-27
Cogstate Limited authorizes a Buyback Plan.	23-02-27	CI
Cogstate Limited announces an Equity Buyback for AUD 13 million worth of its shares.	23-02-27	CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023	23-02-23	CI

Chart Cogstate Limited

Duration

Period

More charts

Company Profile

Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimerâs disease and Parkinsonâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Cogstate Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.325 AUD

Average target price

1.8 AUD

Spread / Average Target

+35.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COGSTATE LIMITED	-8.30%	147M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.24%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research